Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Convertible Debt (2016 - 2021)

Northwest Biotherapeutics (NWBO) has 11 years of Convertible Debt data on record, last reported at $300000.0 in Q4 2021.

  • For Q4 2021, Convertible Debt changed 0.0% year-over-year to $300000.0; the TTM value through Dec 2021 reached $300000.0, changed 0.0%, while the annual FY2021 figure was $300000.0, 0.0% changed from the prior year.
  • Convertible Debt reached $300000.0 in Q4 2021 per NWBO's latest filing, roughly flat from $300000.0 in the prior quarter.
  • Across five years, Convertible Debt topped out at $6.6 million in Q1 2018 and bottomed at $240000.0 in Q1 2020.
  • Average Convertible Debt over 4 years is $3.3 million, with a median of $5.1 million recorded in 2017.
  • Peak YoY movement for Convertible Debt: tumbled 49.61% in 2017, then increased 20.27% in 2018.
  • A 4-year view of Convertible Debt shows it stood at $6.0 million in 2017, then fell by 13.68% to $5.2 million in 2018, then plummeted by 94.22% to $300000.0 in 2020, then changed by 0.0% to $300000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $300000.0 in Q4 2021, $300000.0 in Q4 2020, and $315000.0 in Q3 2020.